Enkephalinase-inhibiting peptides
A distinctive class of research peptides produces anxiolytic effects not by binding the GABA-A receptor but by extending the active life of endogenous enkephalin peptides. The mechanism is indirect, the pharmacology is non-sedating, and the side-effect profile is fundamentally different from the benzodiazepine class. This page explains how it works.
Why this matters
The benzodiazepine problem
For most of clinical pharmacology's history, the standard approach to anxiolysis has been GABA-A receptor positive allosteric modulation. Benzodiazepines, Z-drugs, and their structural relatives all bind GABA-A and amplify the brain's principal inhibitory neurotransmitter. The effect is anxiolytic, but the same mechanism that reduces anxiety also produces sedation, motor impairment, anterograde amnesia, dependence on chronic use, and rebound anxiety on discontinuation.
These side effects are not incidental — they are mechanistic. The same GABA-A activation that quiets the limbic system also slows motor control, impairs new memory formation, and adapts toward dependence when sustained over weeks. A different mechanistic approach is needed if anxiolysis without those effects is the research goal.
The enkephalinase-inhibiting peptides represent one such approach. Rather than directly amplifying inhibition, they extend the active life of endogenous anti-anxiety peptides that the body already releases at low tone. The pharmacology is upstream of GABA-A in the regulatory circuitry — and the side-effect profile is correspondingly different.
The mechanism
How enkephalinase inhibition produces anxiolysis
1. Endogenous enkephalin release
2. Rapid enkephalinase degradation
3. Peptide inhibition of the enzymes
4. Anxiolysis without sedation
The family
Peptides in the enkephalinase-inhibitor class
What this is not
Important mechanistic distinctions
Enkephalinase inhibition is not the same as direct opioid receptor agonism. The mechanism does not introduce an exogenous compound that binds opioid receptors; it extends the active life of endogenous compounds the body has already released. Functionally this is upstream of the receptor in the same way that a serotonin reuptake inhibitor is upstream of serotonin receptors. The downstream effects share vocabulary with direct opioid pharmacology but the pharmacokinetics, the addiction liability, and the safety profile are different.
The enkephalinase-inhibiting peptides do not, on the published evidence, produce opioid-like euphoria, sedation, or respiratory depression at studied doses. They do not show dependence in animal models. They are not classified as controlled substances in any major jurisdiction. The mechanism delivers anxiolytic effects specifically — not the broader opioid pharmacology.
Equally, this is not a complete replacement for benzodiazepine-class drugs in clinical terms. Benzodiazepines produce rapid, dose-titratable anxiolysis with predictable dose-response and decades of clinical refinement behind their use. The enkephalinase-inhibiting peptides produce more gradual, less precisely titrated effects and lack the clinical infrastructure of the benzodiazepine class. Different tools for different research questions.